3 results
PRIMARY OBJECTIVE:To assess the safety and tolerability of MOR202 treatment in subjects with aMNKEY SECONDARY OBJECTIVE:To assess the effect of MOR202 on serum anti-PLA2R antibodies in subjects with aMNSECONDARY OBJECTIVES:1. To assess…
The primary safety endpoint is to evaluate a 30-day major adverse event (MAE) rate, where MAE is a composite of the following device- or procedure-related events: * All-cause mortality* Stroke* Life-threatening bleeding (MVARC scale)* Major vascular…
The primary aim of the trial is to demonstrate the non-inferiority of CSL222 (formerly AMT-061) (2 × 1013 gc/kg) during the 52 weeks following establishment of stable factor IX expression (months 6 to 18) post-treatment (CSL222 (formerly AMT-061))…